阿斯利康高血压新药III期研究再获成功

药事纵横
Oct 09

10月7日,阿斯利康宣布,其在研药物巴多司他(baxdrostat)的III期临床试验再获成功。此次Bax24试验聚焦该药物对顽固性高血压患者24小时血压的控制效果,研究结果将提交至监管机构,并于下月在美国心脏协会(AHA)科学会议的最新突破专场中公布。该研究共纳入218名顽固性高血压患者,将其随机分为两组,在标准治疗基础上,分别接受每日一次口服2mg巴多司他或安慰剂治疗。试验主要终点为治疗12...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10